Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

Shares of Alterity Therapeutics soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average. The clinical-stage biotech ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...

Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.

Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...

CurePSP announced the recipients of their Collaborative Approaches to Resources, Education and Support (CARES) grants designed to advance best practices in the care of progressive supranuclear palsy ...

Kathleen Stein donated the brain of her brother, Ed Stein, who lived a full life with autism, to further research into the causes of autism and treatments for autism-related illnesses.

Imaging studies have shown brain and cerebellar atrophy. The mechanisms leading to IVIG-induced BP elevation are unclear. BP changes were typically observed minutes after starting infusions ...